Cardano Risk Management B.V. buys 6,799 shares of Eli Lilly and Company $LLY

February 18, 2026

Cardano Risk Management B.V. has acquired an additional 6,799 shares of Eli Lilly and Company in the third quarter, as reported in the company’s recent Form 13F filing with the Securities and Exchange Commission. This move increased their holdings in Eli Lilly by 2.9%, bringing their total shares to 243,316. Eli Lilly and Company now account for about 2.0% of Cardano Risk Management B.V.’s investment portfolio, making it their 13th largest holding. The total value of their holdings in Eli Lilly and Company stands at $185,650,000 based on the most recent SEC filing.

This acquisition by Cardano Risk Management B.V. is part of a trend among large investors making changes to their positions in Eli Lilly and Company. Other notable investors include Vanguard Group Inc., which increased its stake by 0.7% in the third quarter, and Laurel Wealth Advisors LLC, which saw a significant increase in shares during the second quarter.

In terms of recent news impacting Eli Lilly and Company, there has been positive sentiment surrounding their announcement of a $1 billion investment in AI aimed at accelerating drug discovery, the success of the Phase 3 LIBRETTO-432 trial with Retevmo (selpercatinib) in early-stage NSCLC, and the building of a $1.5 billion inventory of a weight-loss pill in preparation for a global launch. These developments have been viewed favorably by analysts and retail investors, positioning Eli Lilly for potential growth and revenue diversification.

The company’s strategic moves beyond GLP-1 drugs, such as RNA cancer programs and AI-enabled discovery, have garnered attention for reducing single-product risk and supporting a multi-pillar growth narrative. While there is general positive sentiment surrounding Eli Lilly’s recent initiatives, the company’s participation in an upcoming health care conference and analyst price target updates indicate that investors are closely monitoring the company’s future plans and market positioning.

Looking at analyst price targets, several brokerages have provided their insight on Eli Lilly and Company. With price target adjustments and ratings ranging from “neutral” to “overweight” and “buy,” there is a consensus among analysts that Eli Lilly and Company holds promise for continued growth and value in the market.

In trading updates, Eli Lilly and Company has seen its stock trading up by 0.2%, with a 52-week low of $623.78 and a high of $1,133.95. The company’s financial health and performance have also shown strength, with solid earnings results beating estimates and significant revenue growth compared to previous quarters. Eli Lilly and Company’s consistent innovation and strategic investments position it as a key player in the pharmaceutical market moving forward.